Navigation Links
The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer

BUFFALO, N.Y., May 9, 2011 /PRNewswire/ -- Kinex Pharmaceuticals, LLC announced today that Dr. Allen Barnett, who served as the Founding Chief Executive Officer, has decided to step aside as CEO.

Dr. Barnett stated "I am delighted to see Kinex Pharmaceuticals evolve from a start-up biotechnology company with only a technology platform to a company with a pipeline of two compounds in pre-IND to phase 2 developments. The recent collaboration established with Hanmi Pharmaceuticals is also an important milestone for Kinex. As the company grows, the need for both scientific and business efforts has increased tremendously. I believe that this is the right time to pass the torch to my successor who will help the company grow. I am delighted to say that I have been able to convince our Executive Chairman, Dr. Johnson Lau to step in to take the lead. I have worked with him for more than a decade in different settings and I am very happy to be able to have somebody with his experience and involvement with Kinex to lead the Company. I remain committed to assist with the growth of Kinex Pharmaceuticals in the many years to come."

Dr. Johnson Lau is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management.  As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals.  Dr. Lau has served as the Senior Director of Antiviral Therapy at Schering-Plough where he played a significant role in the FDA approval of Ribavirin/Interferon and Pegylated interferon alpha-2b. He has more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and is also a Director of the Board of Chelsea Therapeutics (NASDAQ: CHTP) and other privately held companies. Dr. Lau has served as the Executive Chairman of Kinex Pharmaceuticals since its inception.

Dr. Lau stated, "Dr. Allen Barnett is a legend in the pharmaceutical industry. Kinex has advanced under his leadership to an early stage pipeline company. He is the grandfather of Kinex Pharmaceuticals. I am delighted that the Board and I have convinced Dr. Barnett to stay on as President Emeritus and allow us to tap into his vast experience in the pharmaceutical industry to support the future growth of Kinex Pharmaceuticals."

Mr. Chuck Lannon, Vice-Chairman of Kinex Pharmaceuticals, stated, "Allen has contributed tremendously to the establishment of Kinex Pharmaceuticals. We thank him for his excellent service and we are delighted to retain him as President Emeritus so that he can continue to support the growth of Kinex Pharmaceuticals with his scientific experience in the many years to come". Mr. Lannon also stated, "I have worked with Johnson for many years. The Board and the management team are extremely supportive of Dr. Lau and are delighted that he is willing to lead Kinex".

About Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica™ and Opal™ to discover and develop novel drugs for oncology and immune-modulatory diseases.    More information of Kinex Pharmaceuticals can be found at

Kinex Pharmaceuticals, LLC – Caution Regarding Forward-looking Information

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Kinex Pharmaceuticals cautions investors that any forward-looking statements or projections made by Kinex Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected..

Kinex Inquiries:

Lyn M. Dyster, Ph.D.
VP, Operations
Kinex Pharmaceuticals
New York Center of Excellence
701 Ellicott Street
Buffalo, NY 14203
Tel: 716.898.8626

SOURCE Kinex Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
2. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
3. American Board of Internal Medicine President Named to Alzheimers Study Group
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
6. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
9. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
10. Silence Therapeutics Announces Board Changes
11. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
Post Your Comments:
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology:
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Aided by ... today announced an innovative study designed to yield insights into how to detect and ... of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
Breaking Medicine News(10 mins):